Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations.

ABSTRACT:

Background

Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in people with diabetes with no available treatment.

Aim

To explore the effect of testosterone treatment on liver. Testosterone therapy improves insulin resistance and reduces total body fat, but its impact on the liver remains poorly studied.

Methods

This secondary analysis of a 40 wk, randomised, double-blinded, placebo-controlled trial of intramuscular testosterone undecanoate in men with type 2 diabetes and lowered serum testosterone concentrations evaluated the change in hepatic steatosis as measured by liver fat fraction on magnetic resonance imaging (MRI).

Results

Of 88 patients enrolled in the index study, 39 had liver MRIs of whom 20 received testosterone therapy and 19 received p

SUBMITTER: Apostolov R 

PROVIDER: S-EPMC9099110 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature